Nucleic Acid Testing Market – Restraint
The inability or difficulty of nucleic acid testing in obtaining quantitative results from a large
pool of clinical sample, difficulty of using NAT test for susceptibility testing, and higher cost of
nucleic acid testing devices is expected to hamper growth of the nucleic acid testing market.
According to the data published in Asian Journal of Transfusion Science, in February 2014,
NAT is highly sensitive and advanced technique, however, it is associated with high cost and
requires dedicated infrastructure facility, equipment, consumables, and technical expertise.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/nucleic-acid-testing-market-1644
Nucleic Acid Testing Market - Regional Analysis
Geographically, global nucleic acid testing market is segmented into North America, Latin
America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position
in nucleic acid testing market, followed by Europe. This is owing to increasing research and
development studies by various government and pharmaceutical organizations in infectious
disease and cancer diagnosis in North America. For instance, in January 2018, University of
Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges
Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid
testing in remote locations to help enable rapid diagnosis, and rapid treatment of infectious
disease. Furthermore, high prevalence and awareness of cancer among people, in turn opting
for early detection of cancer, is expected to aid in growth of the nucleic acid testing market in
this region. For instance, according to American Cancer Society, data findings, North America
registered higher incidence of cancer in children compared to any other region, in 2012.
Moreover, North America accounted for 13.1% of total estimated cases of cancer, in 2012,
globally, according to the same source.
Asia Pacific is expected to witness fastest growth in the nucleic acid testing market over the
forecast period. This is due to growing demand for efficient and quick diagnostic testing and
increasing focus of major market players to expand their geographical reach in this region. For
instance, in March 2013, Qiagen N.V. launched its careHPV test in China. careHPV is molecular
diagnostic test designed to screen for high risk human papillomavirus (HPV) for low-resource
settings such as areas lacking electricity, water or laboratories. Qiagen also gained the approval
from China's State Food and Drug Administration (SFDA) for careHPV in 2012.
Nucleic Acid Testing Market – Competitive Analysis